Hospices Civils De Lyon — Sponsor Intelligence | 39 EU Trials

Filter these 39 trials by condition, phase, country and more.

Open in Search →

39 Registered trials

20 Recruiting

11 Completed trials

1 Countries active

70 Unique IMPs

100% Results reported

Phase III

Phase II

Phase IV

Phase III: 9 Phase II/III: 3 Phase II: 16 Phase I/II: 3 Phase IV: 5 Phase I (Other): 1 Phase I (FiH): 1 Other: 1

Oversight events:

3 temporary halts 1 urgent safety measure 1 unexpected event 1 corrective measure across 4 trials

View oversight register →

100%

11 of 11 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Gestational trophoblastic tumour 1 Obesity 1 Prostate cancer metastatic 1 Stem cell transplant 1 Anaplastic thyroid cancer 1 Asthma 1 Gastroenteropancreatic neuroendocrine tumour disease 1 Neuroendocrine carcinoma metastatic 1 Peritoneal mesothelioma malignant 1 Sepsis 1 Arrhythmogenic right ventricular dysplasia 1 Limbal stem cell deficiency 1

Top IMPs

DOMVANALIMAB 2 NINTEDANIB 2 SODIUM CHLORIDE 2 ZIMBERELIMAB 2 (1-(111C)METHYLPIPERIDIN-4-YL)METHYL 5-AMINO-6-CHLORO-1,4-BENZODIOXINE-8-CARBOXYLATE 1 [18F]-ALTANSERIN 1 [18F]CPFPX 1 1-[[(3S)-2,3-DIHYDRO-1,4-BENZODIOXIN-3-YL]METHYL]-4-[3-((11C)METHOXYMETHYL)-2-PYRIDINYL]PIPERAZINE 1 4-FLUORO-N-[2-[4-(2-METHOXYPHENYL)PIPERAZIN-1-YL]ETHYL]-N-PYRIDIN-2-YLBENZAMIDE 1 ABACAVIR, LAMIVUDINE 1 BEFIRADOL (18F) 1 BOTULINUM TOXIN TYPE A 1

All trials — page 2

39 total

MAINEPSAN : A Prospective Comparative Randomized Double-blind Placebo-controlled In-Parallel Groups Multicenter, Study to Evaluate the remis… Recruiting

2024-514156-33-00 Phase III 1 country PREDNISONE; RITUXIMAB
GASTRICHIP TRIAL. D2 resection and HIPEC (Hyperthermic IntraPeritoneal Chemoperfusion) in locally advanced gastric carcinoma. Recruiting

2024-516358-23-00 Phase III 1 country
Study on efficacy of nintedanib for treatment of epistaxis in hereditary haemorrhagic telangiectasia (HHT) patients - EPISTOP Ended

2024-518886-89-00 Phase II 1 country NINTEDANIB
Exploratory study of the expression of the serotonergic 5-HT4 receptor in Parkinson's disease Ended

2022-503089-57-00 Phase II/III 1 country (1-(111C)METHYLPIPERIDIN-4-YL)METHYL 5-AMINO-6-CHLORO-1,4-BENZODIOXINE-8-CARBOXY…
IMMUNOGAST: An umbrella phase 2 trial to assess personalized targeted IMMUNOtherapy-based regimens in recurrent advanced/metastatic GASTric … Ended

2024-517816-31-00 Phase II 1 country
TALAMESO : A Three-Cohort Phase II trial to Assess the Efficacy of a Maintenance Treatment with TALAzoparib following First Line Platinum-ba… Ended

2024-514104-14-00 Phase II 1 country TALAZOPARIB
TROPHAMET, a phase I/II trial of Avelumab and METhotrexate in low-risk gestational TROPHoblastic neoplasias as first line treatment Ended

2024-515434-32-00 Phase I/II 1 country
IMMUNORARE5 : A national platform of 5 academic phase II trials coordinated by Lyon university hospital to assess the safety and the efficac… Halted

2024-517254-99-00 Phase II 1 country DOMVANALIMAB; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; ZIMBERELIMAB
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy in women with advanced ovarian cancer Halted

2024-515996-37-00 Phase I (Other) 1 country
TOXSIALO-TRIAL : Evaluation of the long-term efficacy of the injection of botulinum toxin A into the salivary glands versus scopolamine patc… Ended

2024-512160-58-00 Phase IV 1 country BOTULINUM TOXIN TYPE A; HYOSCINE
PLAQUE AND BRAIN INFLAMMATION IN SYMPTOMATIC CAROTID STENOSIS: ROLE OF THE FICOLIN-2 STATEMENT Ended

2023-504573-20-00 Phase II 1 country N,N-DIETHYL-2-(2-(4-(2[(18)F]-FLUOROETHOXY)PHENYL)5,7DIMETHYLPYRAZOLO[1,5A]PYRIM…
Pharmacokinetics of anti-lymphocyte serum in the prevention of GvHD in children and adults receiving allogeneic hematopoietic stem cell tran… Ended

2022-501594-39-00 Phase IV 1 country RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN
Symptoms control and adhErenCe assessment during treatment with mepolizUmab new pREfilled devices. SECURE Ended

2022-501029-19-00 Phase IV 1 country BUDESONIDE, FORMOTEROL FUMARATE DIHYDRATE; FLUTICASONE FUROATE, VILANTEROL; FLUT…
NIRAPK: Study of the relationships between pharmacokinetic properties (PK) and hematological toxicity of niraparib in ovarian cancer Ended

2024-513856-14-00 Phase IV 1 country NIRAPARIB TOSILATE MONOHYDRATE
Pragmatic management of progressive disease in idiopathic pulmonary fibrosis Ended

2024-511427-34-00 Phase III 1 country NINTEDANIB; PIRFENIDONE

Showing 25–39 of 39 trials

← All sponsors A–Z